News and Announcements
Proteomics International Laboratories Interim Financial Report
- Published February 26, 2016 4:58PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th February 2016, ASX Announcement
Proteomics International Laboratories Limited (PILL) is a life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteings. The Company’s business model operates from a proprietary proteomics-based technology platform in three synergistic areas: Diagnostics, Analytical services and Therapeutic drug discovery.
During the half-year PILL focused on the commercialisation of PromarkerD, the world’s first proteomics-derived predictive (prognostic) test for the diagnosis of Diabetic Kidney Disease. PILL is pursuing the commercial adoption of PromarkerD as a Laboratory Developed Test (LDT), standard clinical pathology In vitro Diagnostic Test (IVD) and Companion Diagnostic (CDx). Partnering and licensing discussions with major pharmaceutical and health care companies for PromarkerD were ongoing, and PILL has now established commercialisation discussions in three major health care markets – USA, China and Japan. Discussions will continue to be advanced in the coming reporting period.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
